mesalamine has been researched along with Leukopenia in 9 studies
Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.
Leukopenia: A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine serum C-reactive protein levels and the prevalence of leukopenia in patients with Crohn's disease or ulcerative colitis undergoing treatment with azathioprine and/or mesalazine." | 8.12 | C-reactive protein levels and prevalence of leukopenia in patients with inflammatory bowel disease treated with azathioprine and/or mesalazine: a real-life study. ( Catapani, WR; Santos, RCFD; Takahashi, AAR; Waisberg, J, 2022) |
| "To examine serum C-reactive protein levels and the prevalence of leukopenia in patients with Crohn's disease or ulcerative colitis undergoing treatment with azathioprine and/or mesalazine." | 4.12 | C-reactive protein levels and prevalence of leukopenia in patients with inflammatory bowel disease treated with azathioprine and/or mesalazine: a real-life study. ( Catapani, WR; Santos, RCFD; Takahashi, AAR; Waisberg, J, 2022) |
| "Although leukopenia was associated with higher 6-TG levels (P < 0." | 2.69 | Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. ( Dubinsky, MC; Lamothe, S; Seidman, EG; Sinnett, D; Targan, SR; Théorêt, Y; Yang, HY, 2000) |
| "Despite NUDT15 variants showing significant association with thiopurine-induced adverse events (AEs) in Asians, it remains unclear which variants of NUDT15 or whether additional genetic variants should be tested to predict AEs." | 1.48 | NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study. ( Andoh, A; Araki, H; Endo, K; Hanai, H; Hiraoka, S; Hisamatsu, T; Hokari, R; Ikeya, K; Ishiguro, Y; Kakuta, Y; Kawai, Y; Kinouchi, Y; Kobayashi, T; Masamune, A; Matsumoto, T; Miura, M; Mizuno, S; Moroi, R; Motoya, S; Naganuma, M; Nagasaki, M; Naito, T; Nakagawa, S; Nakagawa, T; Nakamura, S; Nakase, H; Nishida, A; Okamoto, D; Onodera, K; Sakuraba, H; Sasaki, M; Shiga, H; Shimosegawa, T; Shinozaki, M; Suzuki, Y; Takagawa, T; Takahara, M; Toyonaga, T; Yanai, S, 2018) |
| "A 29-year-old male patient with ulcerative colitis, who underwent haemodialysis thrice a week because of severe renal dysfunction." | 1.32 | Sulphasalazine-induced leucopenia in a patient with renal dysfunction. ( Hino, B; Iida, M; Itoh, Y; Joh, Y; Makino, K; Oishi, R; Teshima, D; Yano, T, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Santos, RCFD | 1 |
| Catapani, WR | 1 |
| Takahashi, AAR | 1 |
| Waisberg, J | 1 |
| Kakuta, Y | 1 |
| Kawai, Y | 1 |
| Okamoto, D | 1 |
| Takagawa, T | 1 |
| Ikeya, K | 1 |
| Sakuraba, H | 1 |
| Nishida, A | 1 |
| Nakagawa, S | 1 |
| Miura, M | 1 |
| Toyonaga, T | 1 |
| Onodera, K | 1 |
| Shinozaki, M | 1 |
| Ishiguro, Y | 1 |
| Mizuno, S | 1 |
| Takahara, M | 1 |
| Yanai, S | 1 |
| Hokari, R | 1 |
| Nakagawa, T | 1 |
| Araki, H | 1 |
| Motoya, S | 1 |
| Naito, T | 1 |
| Moroi, R | 1 |
| Shiga, H | 1 |
| Endo, K | 1 |
| Kobayashi, T | 1 |
| Naganuma, M | 1 |
| Hiraoka, S | 1 |
| Matsumoto, T | 1 |
| Nakamura, S | 1 |
| Nakase, H | 1 |
| Hisamatsu, T | 1 |
| Sasaki, M | 1 |
| Hanai, H | 1 |
| Andoh, A | 1 |
| Nagasaki, M | 1 |
| Kinouchi, Y | 1 |
| Shimosegawa, T | 1 |
| Masamune, A | 1 |
| Suzuki, Y | 1 |
| Lee, MN | 1 |
| Kang, B | 1 |
| Choi, SY | 1 |
| Kim, MJ | 1 |
| Woo, SY | 1 |
| Kim, JW | 1 |
| Choe, YH | 1 |
| Lee, SY | 1 |
| Masuda, H | 1 |
| Takahashi, Y | 1 |
| Nishida, Y | 1 |
| Asai, S | 1 |
| Fangbin, Z | 1 |
| Xiang, G | 1 |
| Minhu, C | 1 |
| Liang, D | 1 |
| Feng, X | 1 |
| Min, H | 1 |
| Pinjin, H | 1 |
| Teshima, D | 1 |
| Hino, B | 1 |
| Makino, K | 1 |
| Yano, T | 1 |
| Itoh, Y | 1 |
| Joh, Y | 1 |
| Iida, M | 1 |
| Oishi, R | 1 |
| Casellas, F | 1 |
| Vallano, A | 1 |
| Malagelada, JR | 1 |
| Dubinsky, MC | 1 |
| Lamothe, S | 1 |
| Yang, HY | 1 |
| Targan, SR | 1 |
| Sinnett, D | 1 |
| Théorêt, Y | 1 |
| Seidman, EG | 1 |
| Lowry, PW | 1 |
| Franklin, CL | 1 |
| Weaver, AL | 1 |
| Szumlanski, CL | 1 |
| Mays, DC | 1 |
| Loftus, EV | 1 |
| Tremaine, WJ | 1 |
| Lipsky, JJ | 1 |
| Weinshilboum, RM | 1 |
| Sandborn, WJ | 1 |
1 trial available for mesalamine and Leukopenia
| Article | Year |
|---|---|
Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease.
Topics: Adolescent; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Genotype; Humans; Imm | 2000 |
8 other studies available for mesalamine and Leukopenia
| Article | Year |
|---|---|
C-reactive protein levels and prevalence of leukopenia in patients with inflammatory bowel disease treated with azathioprine and/or mesalazine: a real-life study.
Topics: Adult; Azathioprine; C-Reactive Protein; Humans; Inflammatory Bowel Diseases; Leukopenia; Mesalamine | 2022 |
NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study.
Topics: Alopecia; Antibodies, Monoclonal; Azathioprine; Biomarkers, Pharmacological; Genetic Predisposition | 2018 |
Impact of Genetic Polymorphisms on 6-Thioguanine Nucleotide Levels and Toxicity in Pediatric Patients with IBD Treated with Azathioprine.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colitis, Ulcerative; Crohn Diseas | 2015 |
Comparison of the effect of mesalazine and sulfasalazine on laboratory parameters: a retrospective observational study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Chemical and Drug Induced Liver Injury; Cohort Studi | 2012 |
Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease?
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; China; Drug Interactions; | 2012 |
Sulphasalazine-induced leucopenia in a patient with renal dysfunction.
Topics: Adult; Arylamine N-Acetyltransferase; Colitis, Ulcerative; Gastrointestinal Agents; Humans; Kidney D | 2003 |
Leukopenia and thrombocytopenia as adverse effects of treatment with 5-aminosalicylic suppositories.
Topics: Adult; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; H | 1996 |
Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide.
Topics: Adult; Aminosalicylic Acids; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Azathiop | 2001 |